Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

orward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.  Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

 PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statements of Operations(unaudited)Three Months Ended March 31,Nine Months Ended March 31,2013201220132012REVENUES:

$
-$
23,996$
,361$
2,705OPERATING EXPENSES:Research and development

2,944,5874,705,6627,733,6709,683,112General and administrative

1,079,1971,344,8613,141,7513,473,990Total operating expenses

4,023,7846,050,52310,875,42113,157,102Loss from operations

(4,023,784)(6,026,527)(10,865,060)(13,094,397)OTHER INCOME (EXPENSE):Investment income


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
3. Palatin Technologies To Present At The 25th Annual ROTH Conference
4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Physicians Choice Laboratory Services ... menu, which enables healthcare providers to individualize therapeutic ... evidence-based results, healthcare providers are better able to ... while minimizing risks for adverse drug reactions and ... the FDA [1] more than 2.2 million adverse ...
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... "Organic Electronics Market by Material, by Application, Geography ... report to their offering. Organic electronics, ... a branch of material science which deals with small ... as organic because small molecules and polymers are carbon ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
(Date:10/20/2014)... PLAINSBORO, N.J. (PRWEB) October 20, 2014 ... that the Sidney Kimmel Cancer Center at Thomas ... program. , Through the Strategic Alliance Partnership ... and OncLive will collaborate to raise awareness of ... cancer treatment, and other projects. Clinicians and other ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... the, Nikon Ti Inverted Microscope System to Provide Advanced System ... ... MELVILLE, N.Y., Jan. 29 Nikon Instruments, Inc., (http://www.nikoninstruments.com ... systems, which seamlessly integrates with the new Ti-E,research inverted microscope. ...
... REDWOOD CITY, Calif., Jan. 29 Codexis(R), Inc., ... manufacturing,processes, today introduced the Codex(TM) MicroCyp Plate, a ... companies to more,rapidly identify and synthesize drug metabolites ... Plate is being introduced this week at Informex,2008 ...
... SAN DIEGO, Jan. 29 ChemDiv, Inc., ... announced today,that it has entered into a ... CA. Applying its expertise in medicinal and ... and developing,novel antibacterial compounds. Financial terms of ...
Cached Biology Technology:Nikon Instruments Launches Fully-Automated A1 Confocal Laser Microscope Series 2Nikon Instruments Launches Fully-Automated A1 Confocal Laser Microscope Series 3Nikon Instruments Launches Fully-Automated A1 Confocal Laser Microscope Series 4Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds 2ChemDiv and Achaogen Enter Into a Discovery Collaboration 2
(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... new study published in Cancer Research shows ... and colon cancers—can promote the development of skin cancers ... and survival of sun-damaged skin cells. , Previously considered ... proteins called sirtuins that help regulate genomic stability and ... SIRT6 helps repair DNA damage, which can lead to ...
(Date:10/14/2014)... planet,s leading questions is how to produce enough food ... The Food and Agriculture Organization of the United Nations ... next 40 years to feed a growing global population, ... rise in food production. Plants—grains, cereals, fruits, vegetables, ... Current research must tap into our knowledge of ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... of human beings. Now Tel Aviv University has developed ... lead to new antibiotics and powerful bacteria-based "green" pesticides ... by Prof. Eshel Ben-Jacob of Tel Aviv University,s Department ... Sirota-Madi says that their results deepen science,s knowledge of ...
... cell scientists, bioethicists and experts in law and public ... counter secrecy and self interest. The recommended measures focus ... of intellectual property related to stem cells. In ... British city where members first met in 2006lists five ...
... and monitoring Crohn,s disease. It is a stressful procedure in ... into the large intestine. MRI scans are therefore often used ... and how it is responding to treatment. TU Delft is ... an objective, quantitative method for assessing these MRI scans. The ...
Cached Biology News:The genius of bacteria 2Recommendations issued to counter patent, proprietary barriers to sharing stem cell data 2Recommendations issued to counter patent, proprietary barriers to sharing stem cell data 3EU grant for better monitoring of Crohn's disease using MRI 2EU grant for better monitoring of Crohn's disease using MRI 3
... The product contains 5 ... coated with the monoclonal BerEP4 ... EpCAM (epithelial cell adhesion molecule). ... samples of 2 x 10e7 ...
MOUSE ANTI HUMAN FACTOR I...
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed. Free windows version for academic use....
GFX PCR DNA,Gel Band Purif,100, 1 EA. Category: Nucleotide Sample Handling....
Biology Products: